Research Performance Progress Report Required for Non-SNAP Progress Reports Beginning October 17, 2014
The National Institutes of Health (NIH) currently requires use of the federal wide progress reporting format — known as the RPPR (Research Performance Progress Report) — to submit progress reports for Streamlined Non-competing Award Process (SNAP), fellowship, and multi-year funded awards. In April NIH opened the RPPR for use for all Type 5 Non-SNAP progress reports in anticipation of an October 2014 requirement for RPPR use.
Now, it’s official — all type 5 non-SNAP progress reports submitted on or after October 17, 2014 need to be submitted through the RPPR module of eRA Commons. This announcement is part of NIH’s ongoing transition to requiring the use of the federal government-wide RPPR format for all progress reporting.
NIH’s website on the RPPR provides information on the why, what, and when of the RPPR, with a handy table that lets you know for which types of grants the RPPR is now required, and for which it is still optional.
See more at: http://nexus.od.nih.gov/all/2014/06/30/rppr-required-for-non-snap-progress-reports-beginning-october-17-2014/?utm_source=nexus&utm_medium=email&utm_content=nihupdate&utm_campaign=jun13#sthash.8GUpbgGT.dpuf
The Cleveland StrokeNet is offering a Clinical Research and Training Award focused on training in research methodologies and conduct of research related to cerebrovascular diseases. The Cleveland StrokeNet is a collaboration of clinical cerebrovascular programs at University Hospitals of Cleveland, Cleveland Clinic, MetroHealth Medical Center, and Louis Stokes Cleveland VA Medical Center and is funded by the National Institutes of Neurological Disorders and Stroke (NINDS).
This Clinical Research and Training Award is open to clinical and/or research fellows, postdoctoral fellows and faculty within 5 years of training who wish to devote a significant portion of their career to methodologically rigorous research. It is designed to provide research support to allow the investigator to obtain external grant funding in an area of cerebrovascular research, which could include (but are not limited to) primary prevention, acute management, mechanisms of ischemia, genetics, rehabilitation and recovery, and secondary prevention.
The investigator must spend 50% of their effort on research during the period of the award. Applications are due February 1, 2015.
Send the attached completed application and (2) current CV to Irene Katzan MD at firstname.lastname@example.org.
The Ohio Clinical Trial Collaborative (OCTC)
The Ohio Clinical Trial Collaborative OCTC is developing partnerships with the drug industry to include Biotech and Pharmaceutical industries to perform clinical drug trials phase I-4. The OCTC is a network of Ohio based hospitals led by working groups in areas such as neuro oncology, pediatrics, infectious disease, and neuroscience. The OCTC was launched at the BIO2014 which was attended by 15,000 biotech and pharmaceutical executives in San Diego resulting in numerous leads for potential drug trials.
The OCTC has plans to attend additional biotech and pharmaceuticals shows. The OCTC is looking for additional working groups interested in developing a sell sheet that can then be searched on the World Wide Web and will begin sales and marketing activities to identify opportunities with industry. If there are companies that individuals would like OCTC to target, the group welcomes that feedback.
Review the OCTC working website at: http://ohioclintrials.org.
Contact Joe Peter at 216-702-5314 for more information.
Department of Defense
OFFICE OF STRATEGIC INITIATIVES - CALL FOR SUBMISSIONS
U.S. Army Medical Research and Materiel Command (USAMRMC) Broad Agency Announcement - BAA -15-1
Apply early. Funding is limited and subject to availability.
The BAA is continuously open, and accepts proposals on a rolling basis. Pre-proposals may be submitted and will be evaluated at any time throughout the year.
Scope: The USAMRMC's mission is to provide solutions to medical problems of importance to the American warfighter. Projects must pertain to at least one of the research areas of interest outlined in the BAA.
Funding: Budgets are not capped and must reflect the scope of the work. Funding can be requested for up to 5 years.
Areas of interest:
1. Military Infectious Diseases Research Program
2. Combat Casualty Care Research Program
3. Military Operational Medicine Research Program
4. Clinical and Rehabilitative Medicine Research Program
5. Medical Biological Defense Research Program
6. Medical Chemical Defense Research Program
7. Medical Simulation and Information Sciences Research Program
8. Radiation Health Effects Research Program
9. Special Investment Areas/Innovation Funding
Office of Strategic Initiatives (OSI): Case School of Medicine's OSI can work with you to make sure that you meet the current goals and objectives of the USAMRMC that is paramount for your success. OSI can assist you in preparing a competitive proposal and can help guide your efforts from the first draft of the pre-proposal to submission of the full application.
Timeline: Invitation to submit a Full proposal will be given within 90 days of submission of the pre-proposal. An additional 90 days is provided to the applicant to complete the full application. Allow for at least 6 months between submission of the whitepaper to submission of the full application.
Contact us: If you are planning on submitting a pre-proposal, have questions, or would like more information - contact OSI Project Manager Irene Shaland - email@example.com - 216.368.4970
Foundation Fighting Blindness and Harrington Discovery Institute
Foundation Fighting Blindness and Harrington Discovery Institute have partnered to form, the The National Center for Excellence in Fighting Blindness, a Gund-Harrington initiative. This initiative is focused on accelerating the translation of research findings in inherited retinal degenerative diseases (IRD) with the ultimate goal of developing new therapies to improve and/or restore vision.
• This Initiative seeks to award Gund-Harrington Scholar Awards that recognize innovators throughout the USA whose research has the potential to advance standards of care.
• There will be an average of three awards per year, which will be restricted to researchers working at institutions within the USA. Applications from outside the USA are not accepted.
• The Gund-Harrington Scholar Award provides funding for translational drug development and cell therapy along with non-financial project support to help bridge the gap between laboratory-based research and the clinic.
• Funding up to a total of $900,000 over three years and non-financial support will be provided by the The National Center for Excellence in Fighting Blindness. The non-financial support, provided by a team of pharmaceutical experts, will include project management and experienced industry advice in all aspects of drug development, encompassing chemistry, formulation, toxicology, regulatory, intellectual property and business development.
• Awards will be made to physician-scientists, or scientists with a research team that includes significant involvement of a physician with clinical expertise in the IRD.
• Selected projects must demonstrate a reasonable expectation that they can develop a lead product with strong potential for clinical and commercial application by the end of the three year funding period.
• Multi-disciplinary investigators outside the field of retinal disease are particularly encouraged to apply.
Applicants interested in the Gund-Harrington Scholar Awards must apply through Foundation Fighting Blindness.
For more information about Foundation Fighting Blindness visit the Fighting Blindness website.
If you have news or information that you wish to have included in this
update, please send it via e-mail to Tracy Wilson-Holden at
firstname.lastname@example.org no later than
5 pm on the Monday of the week that the update is to be distributed. If you
know of individuals who may be interested in receiving this update, please forward this e-mail to them. To subscribe or unsubscribe
to Case Research News, email your request to Tora Williams at
Please note: At the time of this transmission, all links functioned.
However, Case Research News cannot guarantee that the information will not move or be